Russ Kaplan is a money manager and newsletter advisor who focuses on buying value-oriented stocks with a multi-year investment horizon; here’s his top idea for conservative investors over the coming year.
One of the most under appreciated stocks on Wall Street is Apple (APPL). The stock is among the bluest of blue chips.
Apple has a financial rating of A++. On every measure we see -- such as price/earning ratio -- Apple is undervalued.
With the death of its founder, investors were skeptical about new leadership, but Tim Cook has done an excellent job. He owns over one million shares of the stock.
Apple is constantly developing new products such as the Apple watch and this is not done as a short-term item being rushed onto the market.
Rather, the company takes a long-term perspective and views its product introductions as something that will constantly be improved over the years.
Best Blue Chip Stocks To Own Right Now: AtriCure Inc.(ATRC)
Advisors' Opinion:- [By Dan Caplinger]
The stock market dropped on Friday after major benchmarks once again responded negatively to what many would have thought would be positive news. The latest employment numbers from the Department of Labor's September report continued to show improving job counts and falling unemployment rates. But some market participants had wanted to see stronger gains in jobs, while others pointed to falling bond prices and rising yields as evidence of fear about the sustainability of current levels of economic growth. Some stocks, however, were able to overcome the dour mood. Chefs' Warehouse (NASDAQ:CHEF), SMART Global Holdings (NASDAQ:SGH), and AtriCure (NASDAQ:ATRC) were among the best performers on the day. Here's why they did so well.
- [By Shane Hupp]
ValuEngine upgraded shares of AtriCure (NASDAQ:ATRC) from a hold rating to a buy rating in a research report report published on Saturday.
A number of other research firms have also weighed in on ATRC. Zacks Investment Research lowered shares of AtriCure from a buy rating to a hold rating in a report on Wednesday, May 2nd. BidaskClub raised shares of AtriCure from a hold rating to a buy rating in a report on Saturday, March 17th. Stifel Nicolaus raised their target price on shares of AtriCure from $22.00 to $23.00 and gave the company a buy rating in a report on Friday, April 27th. Needham & Company LLC raised their target price on shares of AtriCure from $23.00 to $26.00 and gave the company a buy rating in a report on Friday, April 27th. Finally, TheStreet raised shares of AtriCure from a d+ rating to a c- rating in a report on Friday, March 16th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $25.00.
- [By Ethan Ryder]
AtriCure (NASDAQ:ATRC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. “
Best Blue Chip Stocks To Own Right Now: ImmunoGen, Inc.(IMGN)
Advisors' Opinion:- [By Shane Hupp]
News coverage about ImmunoGen (NASDAQ:IMGN) has trended somewhat positive on Monday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ImmunoGen earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.3285082790906 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
- [By Logan Wallace]
ImmunoGen (NASDAQ:IMGN) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Wednesday.
- [By Brian Orelli]
Shares of ImmunoGen (NASDAQ:IMGN) closed down 10.6% on Thursday on no apparent news. The volatile biotech stock is, well, volatile. It's not exactly the first time we've seen a double-digit move on no news.
Best Blue Chip Stocks To Own Right Now: Adaptimmune Therapeutics plc(ADAP)
Advisors' Opinion:- [By Logan Wallace]
Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
- [By ]
Cramer was bearish on Chesapeake Energy (CHK) , Adaptimmune Therapeutics (ADAP) , Icahn Enterprises (IEP) , Bristol-Myers Squibb (BMY) , Quad/Graphics (QUAD) , Spectra Energy Partners (SEP) and L Brands (LB) .
- [By Ethan Ryder]
Adaptimmune Therapeutics (NASDAQ:ADAP) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.20, Bloomberg Earnings reports. Adaptimmune Therapeutics had a negative return on equity of 32.26% and a negative net margin of 185.39%. During the same quarter in the prior year, the business earned ($3.00) EPS.
No comments:
Post a Comment